0000899243-21-025821.txt : 20210624 0000899243-21-025821.hdr.sgml : 20210624 20210624204806 ACCESSION NUMBER: 0000899243-21-025821 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210622 FILED AS OF DATE: 20210624 DATE AS OF CHANGE: 20210624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: George Jean CENTRAL INDEX KEY: 0001291804 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40499 FILM NUMBER: 211044348 MAIL ADDRESS: STREET 1: CRITICAL THERAPEUTICS INC STREET 2: 60 WESTVIEW STREET CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc. CENTRAL INDEX KEY: 0001662244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455429901 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-285-4140 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-22 0 0001662244 Cyteir Therapeutics, Inc. CYT 0001291804 George Jean 128 SPRING ST, BUILDING A, SUITE 510 LEXINGTON MA 02421 1 0 0 0 Common Stock 2021-06-22 4 C 0 2444268 A 2444268 I See Footnote Series B Convertible Preferred Stock 2021-06-22 4 C 0 7500000 D Common Stock 2200187 0 I See Footnote Series C Convertible Preferred Stock 2021-06-22 4 C 0 832026 D Common Stock 244081 0 I See Footnote Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein. /s/ Andrew Gengos, Attorney-in-Fact 2021-06-24